SCHEMBL5536765

SCHEMBL5536765

[O]c1ccc(N2CCN(Cc3cc(Cl)c(Cl)c(Cl)c3)CC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 5/20 0.53
MAPT P10636 3/20 0.50
KDM4E B2RXH2 4/20 0.48
ALDH1A1 P00352 4/20 0.48
GAA P10253 1/20 0.46
LSS P48449 1/20 0.45
HTT P42858 1/20 0.44
POLB P06746 1/20 0.44
CHKA P35790 1/20 0.43
USP2 O75604 1/20 0.43
LMNA P02545 1/20 0.43
THRB P10828 1/20 0.43
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
HTR2B P41595 1/20 0.43
DRD2 P14416 1/20 0.43
DRD3 P35462 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5546676 0.87 SIGMAR1 (0.60) DRD4MAPTKDM4EALDH1A1POLB
SCHEMBL5540523 0.86 DRD4 (0.58) DRD4MAPTKDM4EALDH1A1GAA
SCHEMBL5536775 0.85 DRD4 (0.68) DRD4MAPTKDM4EALDH1A1GAA
SCHEMBL5544927 0.83 MAPT (0.71) DRD4MAPTKDM4EALDH1A1GAA
SCHEMBL5542706 0.81 DRD4 (0.77) DRD4GAAHTR2AHTR2CHTR2B
SCHEMBL5540751 0.79 SIGMAR1 (0.65) DRD4MAPTKDM4EALDH1A1USP2
SCHEMBL5535565 0.78 ALDH1A1 (0.57) DRD4MAPTKDM4EALDH1A1POLB
SCHEMBL5544112 0.78 MAPT (0.74) DRD4MAPTKDM4EGAAPOLB
SCHEMBL5535766 0.77 KDM4E (0.61) DRD4MAPTKDM4EALDH1A1GAA
SCHEMBL5537715 0.77 KDM4E (0.61) DRD4MAPTKDM4EALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 DRD4 368/4885MAPT 4117/4885KDM4E 4854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.